Table of Contents
- Trial overview
- Who was studied
- Treatments compared in the study
- Study design and phase
- What the trial measured
- Why this trial matters
Trial overview
This trial, called VICTORION-CHALLENGE, was a randomized, multicenter, open-label study of Inclisiran Sodium in people with hypercholesterolemia and atherosclerotic cardiovascular disease.[1] It was completed and included 400 participants.[1]
Who was studied
The target population was people with atherosclerotic cardiovascular disease, which means heart or blood vessel disease linked to plaque buildup, and hypercholesterolemia, which means high cholesterol.[1] The trial also used background cholesterol treatment with the best tolerated statin dose, with or without ezetimibe.[1]
Statins named in the trial data were atorvastatin and rosuvastatin, and ezetimibe was also listed as part of standard treatment.[1] This means the study was focused on people already receiving usual cholesterol care, not on untreated participants.[1]
Treatments compared in the study
The study compared Inclisiran Sodium with bempedoic acid for lowering LDL cholesterol.[1] LDL cholesterol is often called “bad” cholesterol because high levels can raise heart risk.[1]
Inclisiran Sodium was studied as part of a combination approach with standard care, and the trial aimed to show better LDL-C lowering than bempedoic acid.[1] The study title also describes it as a superiority trial, which means it was designed to see whether one treatment works better than the other.[1]
Study design and phase
This was a Phase 3 trial, which usually means the treatment is being tested in a larger group to compare how well it works in real patients.[1] It was also randomized, so participants were assigned by chance to the study treatment groups.[1]
The study was multicenter, meaning it took place at more than one site.[1] It was open-label, so the people in the study and the research team knew which treatment was being given.[1]
What the trial measured
The main endpoint was the percent change from baseline in LDL-C levels at day 150.[1] Baseline means the starting measurement before treatment begins, and day 150 means the result was checked about five months later.[1]
This endpoint shows how much the treatment lowered LDL cholesterol over time.[1] In simple terms, the study asked whether Inclisiran Sodium could reduce bad cholesterol more than bempedoic acid when both were used with standard care.[1]
Why this trial matters
People with atherosclerotic cardiovascular disease often need strong cholesterol control because high LDL-C can increase the risk of future heart and blood vessel problems.[1] This trial adds information about how Inclisiran Sodium performs in that setting when compared with another cholesterol-lowering drug.[1]
The trial data focus on one main study, so the most important message is that Inclisiran Sodium is being evaluated as part of a strategy to improve LDL-C lowering in patients who already have cardiovascular disease and high cholesterol.[1]
